Christopher J. Destache, PharmD, FCCP

Christopher J. Destache, PharmD, FCCP

Christopher J. Destache, PharmD, FCCP

Professor
School of Pharmacy and Health Professions, Omaha Campus

Expertise/Specializations

  • BCIDP

Academic Appointments

Department

  • Pharmacy Practice

Position

  • Professor

Secondary Appointment

  • Infectious Disease

Teaching Activity

  • HIV
  • Infectious Diseases

Biography

A more complete listing of scholarship, teaching, and research interests can be found on my Curriculum Vitae.  

Publications and Presentations

Books

  • , pg. 159-164

Articles

  • , 13, 454-464
  • , 8, 1-10
  • , 7, 1-10
  • , doi: 10.1016/j.diagnmicrobio.2019.05.020.
  • , doi.org/10.4155/tde-2018-0072.
  • , DOI: 10.1016/j.ijantimicrag.2019.01.014
  • , doi: 10.1016/j.antiviral.2019.04.007
  • , Dec 18;294:216-225
  • , 2018 Sep 4:e4379. doi:10.1002/bmc.4379
  • , 2018;e4270.
  • , 2018 Jun 6. pii: S0166-3542(18)30248-1.
  • , DOI: 10.1128/AAC.02245-18.
  • , Doi: 10.1016/j.antiviral.2017.12.016.
  • , DOI:10.2174/1570162XI5666171120110145​​​​​​​
  • , doi: 10.1007/s11095-017-2255-7
  • , doi:10.3390/polym9090423.
  • , doi:10.15436/2377-1372.17.1583.​​​​​​
  • , https://doi.org/10.1017/ice.2017.30​​​​​​​
  • , doi: 10.1097/QAD.0000000000001349. PMCID 5283613.​​​​​​
  • , pii:10.1128/AAC.01475-16. https://doi.org/10.1128/aac.01475-16 PCMID 5192106.
  • , 129:473-81.  http://dx.doi.org/10.1016/j.jpba.2016.07.040  PMCID 5003708.
  • , 116(9):588-93. doi: 10.7556/jaoa.2016.116.
  • , https://drive.google.com/file/d/0B6lNiNcuTVQbbE5Tc2dyYUJUcm8/view
  • , 129:473-81.  http://dx.doi.org/10.1016/j.jpba.2016.07.040  PMCID 5003708​​​​​​​.
  • , 60(6):3633-9. doi:10.1128/AAC.00450-16. PMCID 4879396.
  • , pii: S1359-6446(15)00416-X. doi: 10.1016/j.drudis.2015.10.019.
  • , 2015;8 http://dx.doi.org/10.15283/ijsc.2015.8.1.1.
  • , 40(10):46-50.
  • , 8, 106-114
  • , 29, 709-715
  • , 29, 709-715
  • , 11, 416-427
  • , 69, 519-527
  • , 11, 416-427
  • , DOI:10.1371/journal.ppat 1005075.
  • , http://dx.doi.org/10.1063/1.4926584 PMCID:4499042
  • , 2015:e72-86. http://dx.doi.org/10.1331/JAPhA.2015.15508.
  • , 27, 562-566
  • , 59, S179-S184
  • , 59, S154-S161
  • , 34, 941-960
  • , 59 (Suppl) 3), S154-S161
  • , 59 (Suppl 3), S179-S184
  • , 34, 6202-6228
  • , 29(5), 746-754
  • , 21, 172-176
  • , 32, E109-E109
  • , 96, 430-436
  • , 96(3), 430-436
  • , 3, 93-102
  • , 65, 2183-2187
  • , 1, 383-386
  • , 74, 103-103
  • , 74, 26-26
  • , 74, 1-7
  • , 1, 383-386
  • , 65, 2183-2187
  • , 74, Article 103
  • , 74, Article 18
  • , 30:615-26.​​​​​​​
  • , 34, 2170-2180
  • , 44, 968
  • , 22, 241-246
  • , 22:241-246.​​​​​​​
  • , 35, 799-809
  • , 183, 661-669
  • , 6, Article 3
  • , 9, 198
  • , 72, 112
  • , 12:515-519.​​​​​​​
  • , 65, 1347-1357
  • , 27:312-324.​​​​​​​
  • , 358, 148-158
  • , 64, 1294
  • , 108, 2827-2835
  • , 1:340-350​​​​​​​
  • , 80(5):1165-1174​​​​​​​
  • , 70, Article 65
  • , 51, 161-172
  • , 25(7):1691-1700​​​​​​​
  • , 101, 9435-9440
  • , 147:35-42​​​​​​​
  • , 991:319-321​​​​​​​
  • , 991, 319-321
  • , 10, 333-336
  • , 22:1527-1532​​​​​​​
  • , 22, 12S-17S
  • , 21, 1055-1060
  • , 47:611-615​​​​​​​
  • , 47, 611-615
  • , 21, 443-451
  • , 6:392-400​​​​​​​
  • , 3 (Fall):50-53​​​​​​​
  • , 19:1167-1172​​​​​​​
  • , 63 (Spring):34-40
  • , 43(Suppl A):107-113
  • , 18:628-634
  • , 17:989-992
  • , July (Suppl):1-12
  • , 38:977-985
  • , 7(11):84-90.
  • , (Suppl Issue) 28-30.​​​​​​​
  • , 15:608-610
  • , 3:433-436.
  • , 24:79-87.
  • , 13:46-59
  • , 32:833-837
  • , 14:286-291.
  • , 26:763-767​​​​​​​
  • , 123:729-732​​​​​​​
  • , 31:354-357​​​​​​​
  • , 25:231-233.​​​​​​​
  • , 12:427-433.
  • , 12:419-426.​​​​​​​
  • , 26:641-651
  • , 23:33-37.​​​​​​​
  • , 22:554-558.​​​​​​​
  • , 18:394-396​​​​​​​
  • , 19:669-673​​​​​​​
  • ,  http://www.medjournal.com​​​​​​​
  • , 2:6-7,24​​​​​​​

Publications

  • , Abstract #L-345
  • , Abstract #109
  • , Vol. 46
  • , 46(Dec), P3-157

General

  • , pii: heartjnl-2015-308589. doi: 10.1136/heartjnl-2015-308589. [Epub ahead of print]
  • , 27:586-588

Presentations

Research and Scholarship

Research and Scholarship Interests

  • Pharmacology, nanomedicine, HIV

Current Research Projects

  • HIV

Grant Funding Received

  • Use of thermosensitive gel-based tenofovir nanoparticles in a humanized BLT mouse model for HIV prevention. Nebraska Center for Virology Award $50,000/year. 2013-2015. Funded.
  • Combination antiretroviral nanoparticles for treatment in a humanized mouse model of HIV. Nebraska Smoking Tax Fund (LB692) sponsored by Creighton University. $74,850 2013-2014 Funded.
  • R56AI095115-01 09/01/2011-08/30/2013 NIH/NIAID Title: Once monthly antiretroviral nanoparticles for HIV-1 treatment. The goal of this project was to evaluate antiretroviral drugs incorporated into a nanoparticle formulation for HIV treatment in a Hu-BLT mouse model
  • Efficacy of combination antiretroviral nanoparticles in a mouse model of HIV-1. Clinical and Translational Research Grant Program, Creighton University $37,500 2011-2012 Funded
  • Clinical Assessment Program and Teflaro Utilization Registry (CAPTURE). A multicenter, retrospective cohort study to characterize the use of Teflaro in the treatment of patients with acute bacterial skin and skin structure infection or community-acquired pneumonia. Cerexa, Inc. Funded. 2012-2015.
  • 3R15AI076039-01A1S1 01/03/2010-01/02/2011 NIH/NIAID Title: Pharmacology of Antiretroviral Nanoparticle Micelles The goal of this project was to investigate the use of a hollow-fiber system to evaluate the pharmacokinetics of antiretroviral nanoparticles.
  • Combined nanofabrications for antiretroviral prophylaxis. Dr. Annemarie Shibata co-principle investigator. President’s Faculty Research Fund. Creighton University $15,000 2012-2013.
  • Determination of the Efficacy of Nanoparticle driven Antiretroviral Drug Delivery Systems using Cellular Model Systems. Annemarie Shibata, Ph. D., principle investigator. $10,000 CU President’s Faculty Research Fund. 2011-2012. Funded
  • Clinical and economic impact associated with agents used for treatment of suspected or documented infections due to methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and Pseudomonas aeruginosa. Cubist Pharmaceuticals, Inc. Funded. 2012-2013.
  • Warfarin Dosing: Pharmacogenetic Algorithm Compared to Pharmacist Dosing. Angie Goeser, Pharm. D. principle investigator. American College of Clinical Pharmacy Foundation. $20,000 2006-2007. 20% effort. CU Internal Funding $4,000
  • BIC+TAF nanoformulation for PrEP in humanized mice. Wareham Research Fund. Creighton University School of Pharmacy. $25,000/year 2018-2020.
  • Combined antiretroviral drug and CCR5 antibody nanoparticle for HIV-1 prevention. Nebraska cigarette tax LB629. 2017-2019. $74,948. Funded.
  • R01AI117740-01 (Destache) 02/01/2015 – 01/30/2019 3.0 calendar mon. NIAID $308,705 Long-acting antiretroviral nanoparticles for HIV prophylaxis. The goal for this project is to evaluate several antiretroviral drugs incorporated into a nanoparticle formulation for HIV prevention in a Hu-BLT mouse model. No Cost Extension 1/31/2020
  • Evaluation of nanomedicines in the treatment of HIV. National Institute of Allergy & Infectious Diseases (NIAID) $434,988 2014-2016. Not funded.
  • Combination antiretroviral nanoparticles for HIV prophylaxis. National Institute of Allergy & Infectious Diseases (NIAID) $2,315,482 2014-2018. Not funded.
  • Evaluation of ASP and rapid diagnostic test on S. aureus bacteremia outcomes. Merck Inc. $58,100. 2017 Not Funded.
  • Phase 2, Open-Label, Randomized, Multicenter Study to Compare the Efficacy and Safety of Dalbavancin to Standard of Care Antibiotic Therapy for the Completion of Treatment of Patients with Complicated Bacteremia or Documented Infective Endocarditis. Allergan Pharmaceuticals, Inc. 2017-2018.
  • EPSCoR Major Instrument Grant. Dr. E. Jeffrey North co-principle investigator. National Science Fountation. $472,372 2016-2020. Not Funded.
  • BIC+TAF NP for HIV-1 Prevention. Wareham Research Award. Creighton University School of Pharmacy & Health Professions. $50,000 2018-2020. Funded
  • K-2 research award for NHSN AR and AU monitoring. Nebraska Department of Health. $75,000 2017-2018 Funded.
  • K-2 renewal award. Nebraska Department of Health. $25,000 2018-2019 Funded.
  • Design and evaluation of CNS-targeted Antiretroviral Nanoparticles. A. Shibata (PI) Haddix award 1/4/18 $15,000. Funded.
  • R15 AI118550-01 (Shibata A) 02/01/2015-01/30/2018 0.06 calendar mon NIAID $300,000 Integrase inhibitor combination nanomicrobicide for prevention of HIV infection. The goal of this project is to evaluate dolutegravir+cellulose acetate phalate for HIV prevention as a vaginal gel.
  • Eradication of HIV-1 brain reservoirs in the BLT-mouse model. Charles Wood, Ph. D. principle investigator. $3,670,661 NAID 2014-2019. Not funded.

Awards and Honors

  • Department of Medicine Best Fellow Research Award, Creighton University School of Medicine, 2019
  • Encapsulation of hydrophilic antiretroviral drugs in nanocarriers US Provisonal Patent 14/792,288, 2015
  • 14/422,747 Polymeric nanoparticles in a thermosensitive gel Coital-Independent Vaginal Prophylaxis of HIV, 2015
  • US Patent No. 13/132,442 Nanoparticles and Methods of Use, 2014
  • International Patent Cooperation Treaty (PCT) Polymeric Nanoparticles in a Thermosensitive Gel for Coital-Independent Vaginal Prophylaxis of HIV WO 2014/039185 A1, 2014
  • Scholarly Achievement Award, Creighton University School of Pharmacy & Allied Health Professions, 2012
  • International Patent Application No. PCT/US2009/067724 US Provisional Patent 61/697,083, 2009
  • Scholarly Achievement Award, Creighton University School of Pharmacy & Allied Health Professions, 1993